NCT06416488

Brief Summary

This study aims to evaluate the health promotion effects of high-intensity interval training (HIIT) intervention on school-age children who are at high risk for cardiovascular disease (CVD), as well as the long-term adherence and acceptability of HIIT in this population for future application.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
336

participants targeted

Target at P75+ for not_applicable

Timeline
28mo left

Started Jul 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress44%
Jul 2024Sep 2028

First Submitted

Initial submission to the registry

May 9, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 16, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

July 13, 2024

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

3.1 years

First QC Date

May 9, 2024

Last Update Submit

December 9, 2025

Conditions

Keywords

Cardiovascular diseasesMetabolic disordersHigh-Intensity Interval TrainingSchool-aged childrenChildhood obesity

Outcome Measures

Primary Outcomes (1)

  • Number of participants with reversal of at least one cardio-metabolic abnormalities

    The primary outcome is a composite outcome that will be measured by combining multiple reverse outcomes of the following cardiometabolic abnormalities: (1) prediabetes; (2) lipid abnormalities; (3) elevated blood pressure. It is defined as occurring if any cardiometabolic abnormality has a reversal outcome at 3rd month of study phrase. Reversal of cardiometabolic abnormalities is defined as: at 3rd month of study phrase, at least one of the following status changed from abnormal at baseline to normal: i. Prediabetes; ii. Lipid abnormalities; iii. Elevated blood pressure.

    3rd month since baseline

Secondary Outcomes (7)

  • Number of participants with reversal of at least one cardio-metabolic abnormalities

    12th month since baseline

  • Body mass index

    3rd and 12th month since baseline

  • Waist-to-height ratio

    3rd and 12th month since baseline

  • Body fat (%)

    3rd and 12th month since baseline

  • Resting metabolic rate

    3rd and 12th month since baseline

  • +2 more secondary outcomes

Study Arms (2)

HIIT group

EXPERIMENTAL

HIIT group will follow modified HIIT in Tabata mode, at least 3 times per week, with 3-month compulsory period and 9-month follow-up period. General health education on promoting health diet and exercise will be sent to HIIT group via offline and online promotion materials during the whole study period of 12 months.

Behavioral: HIIT interventionBehavioral: General health education

General health education group

ACTIVE COMPARATOR

General health education on promoting health diet and exercise will be sent to general health education group via offline and online promotion materials during the whole study period of 12 months.

Behavioral: General health education

Interventions

Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.

HIIT group

General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.

General health education groupHIIT group

Eligibility Criteria

Age7 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Aged 7-18 years at baseline.
  • At least one of the following cardio-metabolic abnormalities:
  • Prediabetes (Impaired fasting glucose: 5.6 ≤ fasting blood glucose level ≤ 6.9 mmol/L; or Impaired glucose tolerance: 7.8 ≤ blood glucose level after 2 hours postprandial ≤ 11.0 mmol/L).
  • Lipid abnormalities (High-density lipoprotein cholesterol ≤ 1.04 mmol/L; or Low-density lipoprotein cholesterol ≥ 3.37 mmol/L; or Triglycerides ≥ 1.70 mmol/L, or Total cholesterol ≥ 5.18 mmol/L).
  • Elevated blood pressure (Systolic/diastolic blood pressure consistently higher than the 90th percentile for gender, age, and height; or systolic/diastolic blood pressure ≥ 120/80 mmHg).
  • Written consent from participants and their guardians.

You may not qualify if:

  • Previously diagnosed with heart failure, severe malnutrition, immune deficiency, liver or kidney disease, cancer, or other diseases deemed unsuitable for participation.
  • Taking weight loss drugs, or undergone weight loss surgery.
  • Attending behavior-based intervention programs (exercise or diet) within a year.
  • Regular HIIT (at least once per week).
  • Secondary obesity, such as neuropsychiatric disorders, endocrine disorders, sleep apnea syndrome, or other conditions.
  • Unable to take interventions due to health conditions, such as joint diseases, fractures, injuries.
  • Other situations unsuitable for participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, 021, China

RECRUITING

MeSH Terms

Conditions

Metabolic SyndromeCardiovascular DiseasesMetabolic DiseasesPediatric Obesity

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersNutritional and Metabolic DiseasesObesityOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2024

First Posted

May 16, 2024

Study Start

July 13, 2024

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2028

Last Updated

December 16, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations